DNA Methylation Biomarker System for Mortality Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for determining biological age and predicting mortality based on DNA methylation markers are limited in their ability to independently predict all-cause mortality beyond chronological age and traditional risk factors.
Innovation Solution
Incorporating blood cell composition information into DNA methylation-based biomarker estimates, specifically using weighted averages of methylation levels from naive cytotoxic T cells, exhausted cytotoxic T cells, and plasma B cells, to enhance predictive power for mortality.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If DNA methylation-based biomarkers are used to estimate biological age, then the predictive power for mortality is improved, but the ability to independently predict all-cause mortality beyond chronological age and traditional risk factors is limited
Solution Approach 1:
The patent combines DNA methylation-based biological age estimates with blood cell composition data (specifically naive cytotoxic T cells, exhausted cytotoxic T cells, and plasma B cells) to create a composite predictor. This merging of multiple biomarker types enhances the independent predictive capability for all-cause mortality while maintaining the improved measurement precision of biological age estimation.
2Measurement precision
If blood cell composition information is incorporated into DNA methylation-based biomarker estimates, then the predictive power for mortality is enhanced, but the complexity of the biomarker system increases
Solution Approach 1:
The patent segments the complex biomarker system into distinct measurable components: DNA methylation levels at specific CpG sites and blood cell composition parameters. By dividing the overall assessment into these separable segments, the system achieves enhanced predictive power while maintaining manageable complexity through standardized measurement protocols for each component.
3Measurement precision
If weighted averages of methylation levels from specific cell types are used, then the estimation of biological age and epigenetic age acceleration becomes more accurate, but the difficulty of detecting and measuring increases
Solution Approach 1:
The patent uses blood cell composition data as an intermediary to bridge DNA methylation measurements and biological age estimation. The weighted averages of methylation levels from specific cell types (naive cytotoxic T cells, exhausted cytotoxic T cells, plasma B cells) serve as intermediate variables that translate complex epigenetic patterns into accurate biological age estimates while providing a structured measurement framework.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach significantly improves the predictive power of DNA methylation-based biomarkers for mortality, providing a more accurate estimation of biological age and epigenetic age acceleration, thereby identifying individuals at higher risk of all-cause mortality.
Implementation Method 1
measuring a methylation level of a set of methylation markers that allow one to estimate certain cell types in an individual
Data Source
Figure 1A~1H
Figure 2A~2C
Figure 3A~3C
AI summary
A method for determining the epigenetic age acceleration of an individual comprising measuring a methylation level of a set of methylation markers in genomic DNA of an individual. An epigenetic age of the individual is determined based on the measured methylation level. An epigenetic age of the individual is further determined based on a methylation derived weighted average cell count of naive cytotoxic T cells and exhausted cytotoxic T cells in the individual. The determined epigenetic age is then compared to a chronological age of the individual to determine an epigenetic age acceleration of the individual. Instances wherein the epigenetic age is greater than the chronological age of the individual is an indication of an increased risk of all-cause mortality.